Fosamax Osteoporosis Drug Lawsuit

Studies Find Fosamax Increases the Risk for Rare Leg Fracture

Fosamax was heavily marketed following its introduction to the consumer market in 1999. Millions of patients were prescribed Fosamax to treat or prevent Osteoporosis, especially in women going through menopause. However, there are potential dangerous side effects of Fosamax that Merck & Company (manufacturer of Fosamax) failed to alert the public about.

Side Effects of Fosamax

Fosamax (generic name Alendronate Sodium) is in a category of drugs known as Bisphosphonates. Bisphosphonates are effective in preventing bone degeneration. Fosamax is given to Osteoporosis patients to reduce or prevent bone loss as the bones age and become susceptible to such loss.

On October 13, 2010, the FDA warned patients and health care providers about the risk of an atypical thigh bone fracture (called “atypical subtrochanteric”), a rare but serious type of thigh fracture, in people who take Fosamax and similar drugs for the treatment of osteoporosis.  These risks are increased in people using Fosamax for five years or more.

Fosamax, Used to Treat Osteoporosis, Is Linked To Unusual Bone Fractures in The Femur

An atypical femur or thigh fracture occurs with little or no trauma or a drastic event. Any unusual or new thigh or groin pain should be reported to your doctor and you should be evaluated for a femur fracture.  Normally, these are extremely rare fractures, but there has been shown to be a higher incidence among people taking bisphosphonates, including Fosamax, Fosamax Plus D, Actonel, Actonel with Calcium, Boniva, Atelvia, and Reclast.

For more information on Fosamax and its potential side effects, please click here:

The Brandi Law Firm Fosamax Attorneys